Integrity Wealth Advisors Inc. Has $937,000 Holdings in Amgen Inc. $AMGN

Integrity Wealth Advisors Inc. trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 58.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 2,864 shares of the medical research company’s stock after selling 4,085 shares during the period. Integrity Wealth Advisors Inc.’s holdings in Amgen were worth $937,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after buying an additional 961,975 shares in the last quarter. State Street Corp lifted its holdings in shares of Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after acquiring an additional 1,287,310 shares during the period. Capital World Investors boosted its position in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after acquiring an additional 4,302,237 shares in the last quarter. Capital International Investors boosted its position in shares of Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after acquiring an additional 282,219 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

Amgen stock opened at $341.66 on Thursday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The stock has a fifty day moving average price of $341.01 and a two-hundred day moving average price of $345.86. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29. The firm has a market capitalization of $184.40 billion, a P/E ratio of 23.78, a P/E/G ratio of 3.49 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period in the prior year, the company posted $4.90 earnings per share. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts anticipate that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AMGN. Morgan Stanley lifted their target price on shares of Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a research report on Tuesday, June 9th. Mizuho lifted their target price on shares of Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research report on Tuesday. Daiwa Securities Group decreased their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. Truist Financial lifted their target price on shares of Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research report on Friday, May 1st. Finally, Jefferies Financial Group began coverage on shares of Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $354.42.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.85% of the stock is owned by corporate insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.